Herantis Pharma initiates patient recruitment for clinical study with Lymfactin® in breast cancer associated lymphedema
Herantis Pharma Plc
Company release 18 May 2016 at 9:00 am
Herantis Pharma Plc (“Herantis”) has started patient recruitment for its clinical study with Lymfactin® for the treatment of breast cancer associated secondary lymphedema. While the primary endpoint of the study is to assess the safety and tolerability of Lymfactin® the study will also assess the preliminary efficacy of the treatment.